Class Action Lawsuit Reminder from Pomerantz LLP for Investors of aTyr Pharma, Inc. – ATYR
Pomerantz LLP has filed a class action lawsuit against aTyr Pharma, Inc. (ATYR) and investors are encouraged to inquire by December 8, 2025.Summary
Pomerantz LLP announced a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or the “Company”), (NASDAQ:ATYR) concerning potential securities fraud or unlawful business practices. Investors who purchased aTyr securities during the class period are advised to contact Danielle Peyton at [email protected] or 646-581-9980, Ext. 7980, to potentially be appointed Lead Plaintiff. The lawsuit stems from a September 15, 2025, announcement that the EFZO-FIT study, a Phase 3 trial evaluating Efzofitimod for pulmonary sarcoidosis, did not meet its primary endpoint. Following this news, aTyr’s stock price significantly declined, falling $5.01 per share, or 83.17%, to close at $1.01. Pomerantz LLP, a firm specializing in corporate, securities, and antitrust litigation, is seeking to recover damages for affected investors.
(Source：WRBL)